Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers

Excited to see this BigTen met TNBC study @bigtenplus.bsky.social published. Although primary endpt not met, addressed an important question and some interesting observations for future. link.springer.com/article/10.1...